

Aspirin for COVID-19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Running title: Aspirin for COVID-19

RECOVERY Collaborative Group*

*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.

Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: recoverytrial@ndph.ox.ac.uk

Word count:

Abstract – 301 words

Main text – 3085 words

References – 33

Tables & Figures – 2 + 3

Aspirin for COVID-19

28 SUMMARY

29 **Background:** Aspirin has been proposed as a treatment for COVID-19 on the basis
30 of its antithrombotic properties.

31 **Methods:** In this randomised, controlled, open-label platform trial, several possible
32 treatments were compared with usual care in patients hospitalised with COVID-19.
33 Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual
34 standard of care plus 150mg aspirin once daily until discharge or usual standard of
35 care alone using web-based simple (unstratified) randomisation with allocation
36 concealment. The primary outcome was 28-day mortality. The trial is registered with
37 ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

38 **Findings:** Between 01 November 2020 and 21 March 2021, 7351 patients were
39 randomly allocated to receive aspirin and 7541 patients to receive usual care alone.
40 Overall, 1222 (17%) patients allocated to aspirin and 1299 (17%) patients allocated to
41 usual care died within 28 days (rate ratio 0.96; 95% confidence interval [CI] 0.89-1.04;
42 $p=0.35$). Consistent results were seen in all pre-specified subgroups of patients.
43 Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median
44 8 vs. 9 days) and a higher proportion were discharged from hospital alive within 28
45 days (75% vs. 74%; rate ratio 1.06; 95% CI 1.02-1.10; $p=0.0062$). Among those not
46 on invasive mechanical ventilation at baseline, there was no significant difference in
47 the proportion meeting the composite endpoint of invasive mechanical ventilation or
48 death (21% vs. 22%; risk ratio 0.96; 95% CI 0.90-1.03; $p=0.23$). Aspirin use was
49 associated with an absolute reduction in thrombotic events of 0.6% (SE 0.4%) and an
50 absolute increase in major bleeding events of 0.6% (SE 0.2%).

Aspirin for COVID-19

51 **Interpretation:** In patients hospitalised with COVID-19, aspirin was not associated
52 with reductions in 28-day mortality or in the risk of progressing to invasive mechanical
53 ventilation or death but was associated with a small increase in the rate of being
54 discharged alive within 28 days.

55 **Funding:** UK Research and Innovation (Medical Research Council), National Institute
56 of Health Research (Grant ref: MC_PC_19056), and the Wellcome Trust (Grant Ref:
57 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.

58 **Keywords:** COVID-19, aspirin, clinical trial.

59

Aspirin for COVID-19

60 **INTRODUCTION**

61 Thrombosis is a key feature of severe COVID-19, with 5-30% of hospitalised patients
62 (depending on illness severity) experiencing a major venous thromboembolic event
63 (mostly pulmonary embolism) and up to 3% an arterial thromboembolic event,
64 particularly myocardial infarction and ischaemic stroke.^{1,2} The risk of thromboembolic
65 complications is reported to be higher in COVID-19 than in other acute medical
66 illnesses and viral respiratory infections, and is associated with worse prognosis.^{3,4}

67 Antiplatelet therapy may have beneficial effects in severe COVID-19 through several
68 mechanisms including inhibition of platelet aggregation, reduction of platelet-derived
69 inflammation, and blocking thrombogenic neutrophil extracellular traps and
70 disseminated intravascular coagulation.⁵ Aspirin is an affordable, globally available
71 drug which at low doses irreversibly inhibits the COX-1 enzyme which is responsible
72 for production of thromboxane A₂ and pro-inflammatory prostaglandins. Aspirin can
73 reduce both arterial and venous thrombotic events and has been shown to abolish in-
74 vitro hyperactivity in platelets from SARS-CoV-2 infected patients.^{6,7} Existing
75 randomized evidence has shown that 75-150mg aspirin daily is as effective as higher
76 doses in preventing cardiovascular events.⁶

77 Seven clinical trials of aspirin in COVID-19 are registered but none have yet reported
78 on the effect of aspirin therapy in COVID-19. Here we report the results of a large
79 randomised controlled trial of aspirin in patients hospitalised with COVID-19.

80

81 **METHODS**

Aspirin for COVID-19

82 **Study design and participants**

83 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an
84 investigator-initiated, individually randomised, controlled, open-label, platform trial to
85 evaluate the effects of potential treatments in patients hospitalised with COVID-19.
86 Details of the trial design and results for other treatments evaluated (lopinavir-ritonavir,
87 hydroxychloroquine, dexamethasone, azithromycin, tocilizumab, convalescent
88 plasma, and colchicine) have been published previously.⁸⁻¹⁴ The trial is underway at
89 177 hospitals in the United Kingdom, two hospitals in Indonesia, and two hospitals in
90 Nepal (appendix pp 5-25), supported in the UK by the National Institute for Health
91 Research Clinical Research Network. The trial is coordinated by the Nuffield
92 Department of Population Health at the University of Oxford (Oxford, UK), the trial
93 sponsor. The trial is conducted in accordance with the principles of the International
94 Conference on Harmonisation–Good Clinical Practice guidelines and approved by the
95 UK Medicines and Healthcare products Regulatory Agency (MHRA) and the
96 Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol,
97 statistical analysis plan, and additional information are available on the study website
98 www.recoverytrial.net.

99 Patients admitted to hospital were eligible for the trial if they had clinically suspected
100 or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in
101 the opinion of the attending clinician, put the patient at significant risk if they were to
102 participate in the trial. Children aged <18 years were not eligible for randomisation to
103 aspirin. Patients with known hypersensitivity to aspirin, a recent history of major
104 bleeding, or currently receiving aspirin or another antiplatelet treatment were

Aspirin for COVID-19

105 excluded. Written informed consent was obtained from all patients, or a legal
106 representative if they were too unwell or unable to provide consent.

107 **Randomisation and masking**

108 Baseline data were collected using a web-based case report form that included
109 demographics, level of respiratory support, major comorbidities, suitability of the study
110 treatment for a particular patient, and treatment availability at the study site (appendix
111 p33-34). Eligible and consenting adult patients were assigned in a 1:1 ratio to either
112 usual standard of care or usual standard of care plus aspirin using web-based simple
113 (unstratified) randomisation with allocation concealed until after randomisation
114 (appendix p30). For some patients, aspirin was unavailable at the hospital at the time
115 of enrolment or was considered by the managing physician to be either definitely
116 indicated or definitely contraindicated. These patients were excluded from the
117 randomised comparison between usual care plus aspirin and usual care alone.
118 Patients allocated to aspirin were to receive 150 mg by mouth (or nasogastric tube) or
119 per rectum daily until discharge.

120 As a platform trial, and in a factorial design, patients could be simultaneously
121 randomised to other treatment groups: i) azithromycin or colchicine or dimethyl
122 fumarate versus usual care, ii) convalescent plasma or monoclonal antibody (REGN-
123 CoV2) versus usual care, and iii) baricitinib versus usual care (appendix pp 30). Until
124 24 January 2021, the trial also allowed a subsequent randomisation for patients with
125 progressive COVID-19 (evidence of hypoxia and a hyper-inflammatory state) to
126 tocilizumab versus usual care. Participants and local study staff were not masked to
127 the allocated treatment. The trial steering committee, investigators, and all other

Aspirin for COVID-19

128 individuals involved in the trial were masked to aggregated outcome data during the
129 trial.

130 **Procedures**

131 A single online follow-up form was completed when participants were discharged, had
132 died or at 28 days after randomisation, whichever occurred earliest (appendix p 35-
133 41). Information was recorded on adherence to allocated study treatment, receipt of
134 other COVID-19 treatments, duration of admission, receipt of respiratory or renal
135 support, and vital status (including cause of death). In addition, in the UK, routine
136 healthcare and registry data were obtained including information on vital status (with
137 date and cause of death), discharge from hospital, receipt of respiratory support, or
138 renal replacement therapy.

139 **Outcomes**

140 Outcomes were assessed at 28 days after randomisation, with further analyses
141 specified at 6 months. The primary outcome was all-cause mortality. Secondary
142 outcomes were time to discharge from hospital, and, among patients not on invasive
143 mechanical ventilation at randomisation, progression to invasive mechanical
144 ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified
145 subsidiary clinical outcomes were use of non-invasive respiratory support, time to
146 successful cessation of invasive mechanical ventilation (defined as cessation of
147 invasive mechanical ventilation within, and survival to, 28 days), use of renal dialysis
148 or haemofiltration, cause-specific mortality, major bleeding events (defined as
149 intracranial bleeding or bleeding requiring transfusion, endoscopy, surgery or
150 vasoactive drugs), thrombotic events (defined as acute pulmonary embolism, deep
151 vein thrombosis, ischaemic stroke, myocardial infarction or systemic arterial

Aspirin for COVID-19

152 embolism) and major cardiac arrhythmias. Information on suspected serious adverse
153 reactions was collected in an expedited fashion to comply with regulatory
154 requirements.

155 **Statistical Analysis**

156 An intention-to-treat comparison was conducted between patients randomised to
157 aspirin and patients randomised to usual care but for whom aspirin was both available
158 and suitable as a treatment. For the primary outcome of 28-day mortality, the log-rank
159 observed minus expected statistic and its variance were used to both test the null
160 hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the one-
161 step estimate of the average mortality rate ratio. We constructed Kaplan-Meier survival
162 curves to display cumulative mortality over the 28-day period. We used the same
163 method to analyse time to hospital discharge and successful cessation of invasive
164 mechanical ventilation, with patients who died in hospital right-censored on day 29.
165 Median time to discharge was derived from Kaplan-Meier estimates. For the pre-
166 specified composite secondary outcome of progression to invasive mechanical
167 ventilation or death within 28 days (among those not receiving invasive mechanical
168 ventilation at randomisation), and the subsidiary clinical outcomes of receipt of
169 ventilation and use of haemodialysis or haemofiltration, the precise dates were not
170 available and so the risk ratio was estimated instead.

171 Prespecified subgroup analyses (defined by characteristics at randomisation: age,
172 sex, ethnicity, level of respiratory support, days since symptom onset, and use of
173 corticosteroids) were performed for the primary outcome using the statistical test of
174 interaction (test for heterogeneity or trend), in accordance with the prespecified
175 analysis plan (appendix p 113). A sensitivity analysis restricting analysis of the primary

Aspirin for COVID-19

176 outcome to patients with a positive PCR test for SARS-COV-2 was conducted. In
177 addition, post-hoc exploratory analyses of the primary and secondary outcomes by
178 venous thromboprophylaxis treatment at randomisation was conducted. Observed
179 effects within subgroup categories were compared using a chi-squared test for
180 heterogeneity or trend, in accordance with the prespecified analysis plan.

181 Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values
182 are 2-sided and are shown without adjustment for multiple testing. The full database
183 is held by the study team which collected the data from study sites and performed the
184 analyses at the Nuffield Department of Population Health, University of Oxford
185 (Oxford, UK).

186 As stated in the protocol, appropriate sample sizes could not be estimated when the
187 trial was being planned at the start of the COVID-19 pandemic (appendix p 53). As the
188 trial progressed, the trial steering committee, whose members were unaware of the
189 results of the trial comparisons, determined that sufficient patients should be enrolled
190 to provide at least 90% power at a two-sided significance level of 1% to detect a
191 clinically relevant proportional reduction in 28-day mortality of 12.5% between the two
192 groups. Consequently, on 21 March, 2021, the steering committee, masked to the
193 results, closed recruitment to the aspirin comparison as sufficient patients had been
194 recruited.

195 Analyses were performed using SAS version 9.4 and R version 4.0.3. The trial is
196 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

197 **Role of the funding source**

Aspirin for COVID-19

198 The funder of the study had no role in study design, data collection, data analysis, data
199 interpretation, or writing of the report. The corresponding authors had full access to all
200 the data in the study and had final responsibility for the decision to submit for
201 publication.

202

203 **RESULTS**

204 Between 1 November 2020 and 21 March 2021, 14892 (66%) of 22560 patients
205 enrolled into the RECOVERY trial were eligible to be randomly allocated to aspirin (i.e.
206 aspirin was available in the hospital at the time and the attending clinician was of the
207 opinion that the patient had no known indication for or contraindication to aspirin, figure
208 1). 7351 patients were randomly allocated to usual care plus aspirin and 7541 were
209 randomly allocated to usual care alone. The mean age of study participants in this
210 comparison was 59.2 years (SD 14.2) and the median time since symptom onset was
211 9 days (IQR 6 to 12 days) (webtable 1). At randomisation, 5035 patients (34%) were
212 receiving thromboprophylaxis with higher dose low molecular weight heparin (LMWH),
213 8878 (60%) with standard dose LMWH, and 979 (7%) were not receiving
214 thromboprophylaxis.

215 The follow-up form was completed for 7290 (99%) participants in the aspirin group and
216 7457 (99%) participants in the usual care group. Among participants with a completed
217 follow-up form, 6587 (90%) allocated to aspirin received at least one dose and 210
218 (3%) allocated to usual care received at least one dose of aspirin (figure 1; webtable
219 2). Of the 6587 participants allocated to aspirin that received at least one dose of
220 aspirin, 5040 (77%) received aspirin on most days following randomisation ($\geq 90\%$ of
221 the days from randomisation to time to discharge or 28 days after randomisation,

Aspirin for COVID-19

222 whichever was earlier). Use of other treatments for COVID-19 was similar among
223 participants allocated aspirin and among those allocated usual care, with nearly 90%
224 receiving a corticosteroid, about one-quarter receiving remdesivir, and one-eighth
225 receiving tocilizumab (webtable 2).

226 Primary and secondary outcome data are known for 99% of randomly assigned
227 patients. We observed no significant difference in the proportion of patients who met
228 the primary outcome of 28-day mortality between the two randomised groups (1222
229 [17%] patients in the aspirin group vs. 1299 (17%) patients in the usual care group;
230 rate ratio 0.96; 95% confidence interval [CI], 0.89 to 1.04; $p=0.35$; figure 2, table 2).
231 The rate ratio was similar across all pre-specified sub-groups (figure 3). In an
232 exploratory analysis restricted to the 14467 (97%) patients with a positive SARS-CoV-
233 2 test result, the result was virtually identical (rate ratio 0.96, 95% CI 0.89 to 1.04;
234 $p=0.31$).

235 Allocation to aspirin was associated with a reduction of 1 day in median time until
236 discharge alive from hospital compared to usual care (median 8 days vs. 9 days [IQR
237 for each 5 to >28 days]) and an increased rate of discharge alive within 28 days (75%
238 vs. 74%, rate ratio 1.06, 95% CI 1.02 to 1.10, $p=0.0062$) (table 2). Among those not
239 on invasive mechanical ventilation at baseline, the number of patients progressing to
240 the pre-specified composite secondary outcome of invasive mechanical ventilation or
241 death among those allocated to aspirin was similar to that among those allocated to
242 usual care (21% vs. 22%, risk ratio 0.96, 95% CI 0.90 to 1.03, $p=0.23$). There was no
243 evidence that the effect of allocation to aspirin vs. usual care on time until discharge
244 alive from hospital or on invasive mechanical ventilation or death differed between the
245 pre-specified subgroups of patients (webfigure 1, webfigure 2). In a post-hoc

Aspirin for COVID-19

246 exploratory analysis there was no evidence that the effect of allocation to aspirin vs.
247 usual care on the primary and secondary outcomes differed by use of LMWH use at
248 randomisation (webfigure 3).

249 We found no significant differences in the prespecified subsidiary clinical outcomes of
250 cause-specific mortality (webtable 3), use of ventilation, successful cessation of
251 invasive mechanical ventilation, or receipt of renal dialysis or haemofiltration (table 2).

252 As expected with the use of aspirin, the incidence of thrombotic events was lower
253 (4.6% vs. 5.3%; absolute difference 0.6%, SE 0.4%) and the incidence of major
254 bleeding events was higher (1.6% vs. 1.0%; absolute difference 0.6%, SE 0.2%) in
255 the aspirin group (webtable 4). The incidence of new cardiac arrhythmias was similar
256 in the two groups (webtable 5). There were 18 reports of a serious adverse event
257 believed related to aspirin, all of which were due to haemorrhagic events (webtable 6).

258

259 **DISCUSSION**

260 In this large, randomised trial involving over 14,000 patients and over 2000 deaths,
261 allocation to aspirin was not associated with reductions in mortality or, among those
262 not on invasive mechanical ventilation at baseline, the risk of progressing to the
263 composite endpoint of invasive mechanical ventilation or death. Allocation to aspirin
264 was, however, associated with a small increase in the rate of being discharged from
265 hospital alive within 28 days. These results were consistent across the prespecified
266 subgroups of age, sex, ethnicity, duration of symptoms prior to randomisation, level of
267 respiratory support at randomisation, and use of corticosteroids.

Aspirin for COVID-19

268 As expected, allocation to aspirin was associated with an increased risk of major
269 bleeding and a decreased risk of thromboembolic complications, such that for every
270 1000 patients treated with aspirin, approximately 6 more would experience a major
271 bleeding event and approximately 6 fewer would experience a thromboembolic event.
272 The rate of reported thromboembolic events in our study population was low (5.3% in
273 the usual care arm) in comparison with previous reports.^{1,2} This could be related to the
274 widespread use of corticosteroids in the trial population resulting in reduced thrombo-
275 inflammatory stimulus or because of the exclusion of patients already receiving aspirin
276 because of prior cardiovascular disease. It is possible that aspirin might have a more
277 meaningful benefit in populations with a higher thrombotic risk, although there would
278 also likely be a corresponding increase in bleeding risk.¹⁵

279 The pathogenesis of thromboembolism in COVID-19 is likely to be multifactorial.
280 Coagulopathy is common in severe COVID-19 and is associated with an inflammatory
281 state, neutrophil extracellular traps, and poor outcomes.^{2,16-20} Platelet activation is
282 increased as a result (and potentially by direct interaction with the virus), amplifying
283 inflammation locally and triggering immunothrombosis.^{21,22} In addition, SARS-CoV-2
284 infection can cause inflammation, dysfunction, and disruption of the vascular
285 endothelium in multiple organs, potentially via direct entry through the ACE-2
286 receptor.²³⁻²⁵ The resulting endothelial injury and tissue factor exposure promote
287 thrombosis in the pulmonary circulation and other vascular beds, with microangiopathy
288 and alveolar capillary occlusion contributing to the diffuse alveolar damage and
289 hypoxemia seen in COVID-19.^{24,26} Furthermore, in autopsy studies pulmonary
290 microthrombi are nine times more frequent in patients with COVID-19 compared to
291 patients with influenza.²⁴

Aspirin for COVID-19

292 A large number of randomised controlled trials of antithrombotic therapy in COVID-19
293 are registered, including trials of therapeutic doses of heparin, direct acting oral
294 anticoagulants, anti-platelet agents, serine protease inhibitors, and thrombolytics.²⁷ In
295 critically-ill patients, the INSPIRATION, REMAP-CAP, ACTIV-4a and ATTACC trials
296 did not report a benefit in clinical outcomes from therapeutic anticoagulation.^{28,29}
297 Similarly, preliminary results from the COALIZAO-ACTION trial did not show a benefit
298 from therapeutic anticoagulation (either heparin or rivaroxaban) in a combined
299 endpoint of mortality, successful discharge, or need for oxygen in hospitalised patients
300 with elevated D-dimers.³⁰ However, the REMAP-CAP/ACTIV-4a/ATTACC
301 investigators have reported that in non-critically ill COVID-19 patients, compared to
302 thromboprophylaxis doses, heparin at therapeutic doses was associated with an
303 absolute increase of 4.6% (95% credible interval 0.7 to 8.1) in the proportion of
304 participants surviving to hospital discharge without receipt of organ support during the
305 first 21 days.³¹

306 Although there are currently no other published randomised trial data on the use of
307 aspirin in COVID-19, the REMAP-CAP/ACTIV-4a/ATTACC report does suggest that
308 antithrombotic therapy may be important in some patients.³¹ The lack of meaningful
309 benefit from aspirin in our trial could be because antiplatelet therapy confers no
310 significant additional benefit on top of high rates of antithrombotic therapy with LMWH
311 and corticosteroid treatment diminishing thrombo-inflammatory stimulation.
312 Alternatively, other non-platelet pathways leading to thrombosis and alveolar damage
313 may be more important determinants of clinical outcomes.

314 Any potential benefit of antithrombotic therapies in COVID-19 patients may also
315 depend on timing of treatment initiation, especially if thrombi have already developed

Aspirin for COVID-19

316 by the time of admission.³² Thromboembolic events and microthrombi are common in
317 COVID-19 patients on either prophylactic or therapeutic anticoagulation.³³ The
318 apparent lack of benefit in INSPIRATION and the REMAP-CAP/ACTIV-4a/ATTACC
319 severe disease cohorts suggests that these patients might have passed the point at
320 which any benefit from therapeutic anticoagulation could be gained.^{28,29} Although we
321 found no evidence of heterogeneity based on duration of symptoms, baseline disease
322 severity, or background thrombotic prophylaxis regimen, ongoing trials of aspirin in
323 ambulatory populations and those exploring more potent anti-platelet inhibition and
324 fibrinolysis should provide further insights.

325 Strengths of this trial included that it was randomised, had a large sample size, broad
326 eligibility criteria, and 99% of patients were followed up for the primary outcome. The
327 trial also had some limitations. Detailed information on radiological or physiological
328 outcomes was not collected. Although this randomised trial is open label (i.e.,
329 participants and local hospital staff are aware of the assigned treatment), the primary
330 and secondary outcomes are unambiguous and were ascertained without bias through
331 linkage to routine health records. However, it cannot be excluded that reporting of
332 thromboembolic and bleeding events might have been influenced by knowledge of
333 treatment allocation. Nevertheless, the proportional effects of aspirin on these events
334 were very similar to those reported in previous large clinical trials of aspirin in people
335 with prior cardiovascular disease.⁶

336 The RECOVERY trial only studied hospitalised COVID-19 patients and, therefore, is
337 not able to provide evidence on the safety and efficacy of aspirin used in other patient
338 groups. Further studies to identify the safety and efficacy of aspirin in non-hospitalised
339 patients are needed and are ongoing.

Aspirin for COVID-19

340 In summary, the results of this large, randomised trial do not support the addition of
341 aspirin to standard thromboprophylaxis or therapeutic anticoagulation in patients
342 hospitalised with COVID-19.

343

344

Aspirin for COVID-19

345 **Contributors**

346 This manuscript was initially drafted by PWH and MJL, further developed by the
347 Writing Committee, and approved by all members of the trial steering committee. PWH
348 and MJL vouch for the data and analyses, and for the fidelity of this report to the study
349 protocol and data analysis plan. PWH, JKB, MB, LCC, JD, SNF, TJ, EJ, KJ, WSL, AM,
350 AM, KR, GT, MM, RH, and MJL designed the trial and study protocol. MM, MC, G P-
351 A, LP, NB, ST, VC, TB, HT, BE, DC, TW, RS, CG and the Data Linkage team at the
352 RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre
353 staff listed in the appendix collected the data. NS, ES and JRE did the statistical
354 analysis. All authors contributed to data interpretation and critical review and revision
355 of the manuscript. PWH and MJL had access to the study data and had final
356 responsibility for the decision to submit for publication.

357

Aspirin for COVID-19

358 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

359 Peter W Horby,* Guilherme Pessoa-Amorim,* Natalie Staplin,* Jonathan R
360 Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J Brunskill, Simon Tiberi,
361 Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony
362 Whitehouse, Rahuldeb Sarkar, Clive Graham, J Kenneth Baillie, Buddha Basnyat,^q
363 Maya H Buch, Lucy C Chappell, Jeremy Day, Saul N Faust, Raph L Hamers,
364 Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery,
365 Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham,⁺ Richard
366 Haynes,⁺ Martin J Landray.⁺

367 * PWH, GPA and NS made an equal contribution

368 + MM, RH and MJL made an equal contribution

369 **Data Monitoring Committee**

370 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
371 Mohammed Munavvar (from January 2021), Ian Roberts (until December 2020),
372 Janet Wittes.

373 **Declaration of interests**

374 The authors have no conflict of interest or financial relationships relevant to the
375 submitted work to disclose. No form of payment was given to anyone to produce the
376 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure
377 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the
378 University of Oxford has a staff policy of not accepting honoraria or consultancy fees

Aspirin for COVID-19

379 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)
380 [independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

381 **Data sharing**

382 The protocol, consent form, statistical analysis plan, definition & derivation of clinical
383 characteristics & outcomes, training materials, regulatory documents, and other
384 relevant study materials are available online at www.recoverytrial.net. As described in
385 the protocol, the trial Steering Committee will facilitate the use of the study data and
386 approval will not be unreasonably withheld. Deidentified participant data will be made
387 available to bona fide researchers registered with an appropriate institution within 3
388 months of publication. However, the Steering Committee will need to be satisfied that
389 any proposed publication is of high quality, honours the commitments made to the
390 study participants in the consent documentation and ethical approvals, and is
391 compliant with relevant legal and regulatory requirements (e.g. relating to data
392 protection and privacy). The Steering Committee will have the right to review and
393 comment on any draft manuscripts prior to publication. Data will be made available in
394 line with the policy and procedures described at: [https://www.ndph.ox.ac.uk/data-](https://www.ndph.ox.ac.uk/data-access)
395 [access](https://www.ndph.ox.ac.uk/data-access). Those wishing to request access should complete the form at
396 https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx
397 and e-mail to: data.access@ndph.ox.ac.uk

398

399 **Acknowledgements**

400 Above all, we would like to thank the thousands of patients who participated in this
401 trial. We would also like to thank the many doctors, nurses, pharmacists, other allied

Aspirin for COVID-19

402 health professionals, and research administrators at 176 NHS hospital organisations
403 across the whole of the UK, supported by staff at the National Institute of Health
404 Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England,
405 Department of Health & Social Care, the Intensive Care National Audit & Research
406 Centre, Public Health Scotland, National Records Service of Scotland, the Secure
407 Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in
408 England, Scotland, Wales and Northern Ireland.

409 The RECOVERY trial is supported by grants to the University of Oxford from UK
410 Research and Innovation (UKRI)/NIHR (Grant reference: MC_PC_19056), the
411 Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid
412 Response Grant (COV19-RECPLA) and the Wellcome Trust (Grant Ref:
413 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator. Core funding is
414 provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and
415 Melinda Gates Foundation, the Foreign, Commonwealth and development
416 Department, Health Data Research UK, the Medical Research Council Population
417 Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic
418 Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant
419 from UK Medical Research Council (MC_UU_00002/14) and an NIHR Senior
420 Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding
421 provided by NIHR Nottingham Biomedical Research Centre. Combiphar supplied
422 colchicine free of charge for use in this trial in Indonesia. Abbvie contributed some
423 supplies of lopinavir-ritonavir for use in this trial. Tocilizumab was provided free of
424 charge for this trial by Roche Products Limited. REGN-COV2 was provided free of
425 charge for this trial by Regeneron.

Aspirin for COVID-19

426 The views expressed in this publication are those of the authors and not necessarily
427 those of the NHS or the NIHR.

428 **Conflicts of interest**

429 The authors have no conflict of interest or financial relationships relevant to the
430 submitted work to disclose. No form of payment was given to anyone to produce the
431 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure
432 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the
433 University of Oxford has a staff policy of not accepting honoraria or consultancy fees
434 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-
435 independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

436

Aspirin for COVID-19

437 References

- 438 1. Jimenez D, Garcia-Sanchez A, Rali P, et al. Incidence of VTE and Bleeding
439 Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review
440 and Meta-analysis. *Chest* 2021; **159**(3): 1182-96.
- 441 2. Kunutsor SK, Laukkanen JA. Incidence of venous and arterial
442 thromboembolic complications in COVID-19: A systematic review and meta-analysis.
443 *Thromb Res* 2020; **196**: 27-30.
- 444 3. Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high
445 cumulative incidence of thrombotic complications in critically ill ICU patients with
446 COVID-19: An updated analysis. *Thromb Res* 2020; **191**: 148-50.
- 447 4. Smilowitz NR, Subashchandran V, Yuriditsky E, et al. Thrombosis in
448 hospitalized patients with viral respiratory infections versus COVID-19. *Am Heart J*
449 2021; **231**: 93-5.
- 450 5. Carestia A, Davis RP, Grosjean H, Lau MW, Jenne CN. Acetylsalicylic acid
451 inhibits intravascular coagulation during Staphylococcus aureus-induced sepsis in
452 mice. *Blood* 2020; **135**(15): 1281-6.
- 453 6. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of
454 antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
455 risk patients. *BMJ* 2002; **324**(7329): 71-86.
- 456 7. Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and
457 function in patients with COVID-19. *Blood* 2020; **136**(11): 1317-29.
- 458 8. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-
459 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a
460 randomised, controlled, open-label, platform trial. *Lancet* 2020; **396**(10259): 1345-
461 52.
- 462 9. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
463 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;
464 **383**(21): 2030-40.
- 465 10. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in
466 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
- 467 11. RECOVERY Collaborative Group. Azithromycin in patients admitted to
468 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label,
469 platform trial. *Lancet* 2021; **397**(10274): 605-12.
- 470 12. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
471 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
472 *Lancet* 2021; **397**(10285): 1637-45.
- 473 13. RECOVERY Collaborative Group. Convalescent plasma in patients admitted
474 to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label,
475 platform trial. *Lancet* 2021.

Aspirin for COVID-19

- 476 14. RECOVERY Collaborative Group, Horby PW, Campbell M, et al. Colchicine in
477 patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
478 controlled, open-label, platform trial. *medRxiv* 2021: 2021.05.18.21257267.
- 479 15. Antithrombotic Trialists C, Baigent C, Blackwell L, et al. Aspirin in the primary
480 and secondary prevention of vascular disease: collaborative meta-analysis of
481 individual participant data from randomised trials. *Lancet* 2009; **373**(9678): 1849-60.
- 482 16. Jin S, Jin Y, Xu B, Hong J, Yang X. Prevalence and Impact of Coagulation
483 Dysfunction in COVID-19 in China: A Meta-Analysis. *Thromb Haemost* 2020;
484 **120**(11): 1524-35.
- 485 17. Zhang A, Leng Y, Zhang Y, et al. Meta-analysis of coagulation parameters
486 associated with disease severity and poor prognosis of COVID-19. *Int J Infect Dis*
487 2020; **100**: 441-8.
- 488 18. Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue
489 factor-enriched neutrophil extracellular traps are key drivers in COVID-19
490 immunothrombosis. *J Clin Invest* 2020; **130**(11): 6151-7.
- 491 19. Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps
492 contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome.
493 *Blood* 2020; **136**(10): 1169-79.
- 494 20. Petitto E, Falcinelli E, Paliani U, et al. Association of Neutrophil Activation,
495 More Than Platelet Activation, With Thrombotic Complications in Coronavirus
496 Disease 2019. *J Infect Dis* 2021; **223**(6): 933-44.
- 497 21. Taus F, Salvagno G, Cane S, et al. Platelets Promote Thromboinflammation
498 in SARS-CoV-2 Pneumonia. *Arterioscler Thromb Vasc Biol* 2020; **40**(12): 2975-89.
- 499 22. Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance
500 thrombosis in COVID-19. *J Hematol Oncol* 2020; **13**(1): 120.
- 501 23. Hariri LP, North CM, Shih AR, et al. Lung Histopathology in Coronavirus
502 Disease 2019 as Compared With Severe Acute Respiratory Syndrome and H1N1
503 Influenza: A Systematic Review. *Chest* 2021; **159**(1): 73-84.
- 504 24. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular
505 Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J Med* 2020;
506 **383**(2): 120-8.
- 507 25. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and
508 endotheliitis in COVID-19. *Lancet* 2020; **395**(10234): 1417-8.
- 509 26. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a
510 series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet*
511 *Infect Dis* 2020.
- 512 27. Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent Randomized Trials of
513 Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
514 *J Am Coll Cardiol* 2021; **77**(15): 1903-21.

Aspirin for COVID-19

- 515 28. Zarychanski R. Therapeutic Anticoagulation in Critically Ill Patients with Covid-
516 19 – Preliminary Report. *medRxiv* 2021: 2021.03.10.21252749.
- 517 29. Inspiration Investigators, Sadeghipour P, Talasaz AH, et al. Effect of
518 Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic
519 Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among
520 Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION
521 Randomized Clinical Trial. *JAMA* 2021; **325**(16): 1620-30.
- 522 30. R. D. Lopes. AntiCoagulaTlon cOroNavirus - ACTION. 2021. AntiCoagulaTlon
523 cOroNavirus - American College of Cardiology (acc.org) (accessed 22 May 2021
524 2021).
- 525 31. Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation in Non-
526 Critically Ill Patients with Covid-19. *medRxiv* 2021: 2021.05.13.21256846.
- 527 32. Yamakawa K, Umemura Y, Murao S, Hayakawa M, Fujimi S. Optimal Timing
528 and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated
529 Intravascular Coagulation. *Clin Appl Thromb Hemost* 2019; **25**: 1076029619835055.
- 530 33. Klok FA, Kruij M, van der Meer NJM, et al. Incidence of thrombotic
531 complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020; **191**:
532 145-7.
533
- 534

Aspirin for COVID-19

535

536 **Figures**

537 **Figure 1: Trial profile**

538 ITT=intention to treat. *Number recruited overall during period that adult participants
539 could be recruited into aspirin comparison. † Includes 379/7351 (5.2%) patients in
540 the aspirin arm and 407/7541 (5.4%) patients in the usual care arm allocated to
541 tocilizumab.

542 **Figure 2: Effect of allocation to aspirin on 28-day mortality**

543 **Figure 3: Effect of allocation to aspirin on 28-day mortality by baseline** 544 **characteristics**

545 Subgroup-specific rate ratio estimates are represented by squares (with areas of the
546 squares proportional to the amount of statistical information) and the lines through
547 them correspond to the 95% CIs. The ethnicity, days since onset and use of
548 corticosteroids subgroups exclude those with missing data, but these patients are
549 included in the overall summary diamond.

550

Aspirin for COVID-19

551 **Table 1: Baseline characteristics**

	Treatment allocation	
	Aspirin (n=7351)	Usual care (n=7541)
Age, years	59.2 (14.1)	59.3 (14.3)
<70	5658 (77%)	5786 (77%)
≥70 to <80	1163 (16%)	1165 (15%)
≥80	530 (7%)	590 (8%)
Sex		
Male	4570 (62%)	4631 (61%)
Female*	2781 (38%)	2910 (39%)
Ethnicity		
White	5474 (74%)	5655 (75%)
Black, Asian, and minority ethnic	1176 (16%)	1202 (16%)
Unknown	701 (10%)	684 (9%)
Number of days since symptom onset	9 (7-12)	9 (6-12)
Number of days since hospitalisation	1 (1-3)	2 (1-3)
Respiratory support received		
None/simple oxygen	4936 (67%)	5036 (67%)
Non invasive ventilation	2057 (28%)	2133 (28%)
Invasive mechanical ventilation	358 (5%)	372 (5%)
Biochemistry		
C-reactive protein, mg/L	88 (47-146)	91 (47-150)
Creatinine, umol/L	76 (63-93)	76 (62-92)
D-dimer, ng/mL	475 (205-1088)	489 (210-1083)
Previous diseases		
Diabetes	1588 (22%)	1659 (22%)
Heart disease	776 (11%)	788 (10%)
Chronic lung disease	1425 (19%)	1411 (19%)
Tuberculosis	20 (<0.5%)	21 (<0.5%)
HIV	25 (<0.5%)	21 (<0.5%)
Severe liver disease†	67 (1%)	53 (1%)
Severe kidney impairment‡	214 (3%)	251 (3%)
Any of the above	3154 (43%)	3247 (43%)
Use of corticosteroids		
Yes	6906 (94%)	7109 (94%)
No	441 (6%)	425 (6%)
Missing	4 (<0.5%)	7 (<0.5%)
Severe acute respiratory syndrome coronavirus 2 test result		
Positive	7140 (97%)	7327 (97%)
Negative	87 (1%)	86 (1%)
Unknown	124 (2%)	128 (2%)

Results are count (%), mean ± standard deviation, or median (inter-quartile range). *Includes 58 pregnant women. †Defined as requiring ongoing specialist care. ‡Defined as estimated glomerular filtration rate <30 mL/min/1.73m²

Aspirin for COVID-19

553 **Table 2: Effect of allocation to aspirin on key study outcomes**


	Treatment allocation		RR (95% CI)	p value
	Aspirin (n=7351)	Usual care (n=7541)		
Primary outcome:				
28-day mortality	1222 (17%)	1299 (17%)	0.96 (0.89-1.04)	0.35
Secondary outcomes:				
Median time to being discharged alive, days	8 (5 to >28)	9 (5 to >28)		
Discharged from hospital within 28 days	5496 (75%)	5548 (74%)	1.06 (1.02-1.10)	0.0062
Receipt of invasive mechanical ventilation or death*	1473/6993 (21%)	1569/7169 (22%)	0.96 (0.90-1.03)	0.23
Invasive mechanical ventilation	772/6993 (11%)	829/7169 (12%)	0.95 (0.87-1.05)	0.32
Death	1076/6993 (15%)	1141/7169 (16%)	0.97 (0.90-1.04)	0.39
Subsidiary clinical outcomes				
Use of ventilation	1131/4936 (23%)	1198/5036 (24%)	0.96 (0.90-1.03)	0.30
Non-invasive ventilation	1101/4936 (22%)	1162/5036 (23%)	0.97 (0.90-1.04)	0.36
Invasive mechanical ventilation	296/4936 (6%)	325/5036 (6%)	0.93 (0.80-1.08)	0.35
Successful cessation of invasive mechanical ventilation	135/358 (38%)	135/372 (36%)	1.08 (0.85-1.37)	0.54
Renal replacement therapy	273/7291 (4%)	282/7480 (4%)	0.99 (0.84-1.17)	0.93

RR=Rate Ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). CI=confidence interval. *Analyses exclude those on invasive mechanical ventilation at randomization.

554

555

Figure 1: Trial profile



ITT=intention to treat. *Number recruited overall during period that adult participants could be recruited into aspirin comparison.
† Includes 379/7351 (5.2%) patients in the aspirin arm and 407/7541 (5.4%) patients in the usual care arm allocated to tocilizumab.

Figure 2: Effect of allocation to aspirin on 28-day mortality




Figure 3: Effects of allocation to aspirin on 28-day mortality by baseline characteristics

